| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, …
Over the last 12 months, insiders at Alaunos Therapeutics, Inc. have bought $0 and sold $0 worth of Alaunos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Alaunos Therapeutics, Inc. have bought $657,000 and sold $13,711 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750,000 shares for transaction amount of $487,500 was made by Postma Robert W (director) on 2022‑11‑29.
| 2024-12-31 | Sale | Vieser Jaime | director | 3,000 0.1921% | $2.01 | $6,022 | +38.22% | |
| 2023-09-01 | Sale | Boyle Kevin S. Sr. | Chief Executive Officer | 68,014 0.0277% | $0.14 | $9,542 | -40.66% | |
| 2022-11-29 | Postma Robert W | director | 750,000 0.3334% | $0.65 | $487,500 | -26.47% | ||
| 2022-11-29 | Vieser Jaime | director | 1.25M 0.5557% | $0.65 | $812,500 | -26.47% | ||
| 2021-12-22 | Sale | De Groot Eleanor | EVP, Operations | 20,132 0.0094% | $1.27 | $25,568 | -25.70% | |
| 2021-11-17 | Boyle Kevin S. Sr. | Chief Executive Officer | 9,116 0.0044% | $1.40 | $12,762 | -20.22% | ||
| 2021-11-16 | Boyle Kevin S. Sr. | Chief Executive Officer | 884 0.0004% | $1.40 | $1,238 | -22.70% | ||
| 2021-09-29 | Vieser Jaime | director | 100,000 0.0464% | $1.91 | $191,000 | -40.63% | ||
| 2021-09-02 | Postma Robert W | director | 75,000 0.0342% | $1.73 | $129,750 | -35.59% | ||
| 2021-09-02 | Hagen Heidi | director | 23,770 0.011% | $1.76 | $41,835 | -35.59% | ||
| 2021-09-01 | Weis Holger | director | 50,000 0.0238% | $1.83 | $91,500 | -36.31% | ||
| 2021-09-01 | Huang James | director | 100,000 0.0445% | $1.71 | $171,000 | -36.31% | ||
| 2021-01-08 | Sale | Buck Jill | EVP, GM Gene Therapy | 27,894 0.0129% | $3.12 | $87,029 | -22.47% | |
| 2021-01-08 | Sale | Hadfield Robert | General Counsel and Secretary | 26,500 0.0122% | $3.12 | $82,680 | -22.47% | |
| 2021-01-08 | Sale | Lafond Kevin G | SVP, Treasurer & CAO | 18,020 0.0082% | $3.09 | $55,682 | -22.47% | |
| 2021-01-04 | Sale | Cooper Laurence James Neil | President and CEO | 105,693 0.0475% | $2.71 | $286,428 | -9.93% | |
| 2021-01-04 | Sale | De Groot Eleanor | EVP, GM Cell Therapy | 21,620 0.0097% | $2.72 | $58,806 | -9.93% | |
| 2020-01-02 | Sale | MAUNEY DAVID M MD | President | 22,394 0.011% | $4.55 | $101,893 | -37.61% | |
| 2020-01-02 | Sale | De Groot Eleanor | EVP, GM Cell Therapy | 24,890 0.0123% | $4.55 | $113,250 | -37.61% | |
| 2020-01-02 | Sale | Buck Jill | EVP, GM Gene Therapy | 27,923 0.0138% | $4.55 | $127,050 | -37.61% |
| Postma Robert W | director | 5000000 145.3206% | $9.3M | 2 | 0 | <0.0001% |
| Cooper Laurence James Neil | President and CEO | 1799280 52.2945% | $3.35M | 1 | 2 | <0.0001% |
| Boyle Kevin S. Sr. | Chief Executive Officer | 798236 23.2% | $1.48M | 2 | 1 | <0.0001% |
| MAUNEY DAVID M MD | President | 195278 5.6756% | $363,217.08 | 1 | 1 | <0.0001% |
| Hagen Heidi | director | 145889 4.2401% | $271,353.54 | 1 | 0 | <0.0001% |
| Weis Holger | director | 120167 3.4925% | $223,510.62 | 1 | 0 | <0.0001% |
| Huang James | director | 108333 3.1486% | $201,499.38 | 1 | 0 | <0.0001% |
| KIRK RANDAL J | 100000 2.9064% | $186,000.00 | 14 | 0 | +1.39% | |
| Fowler Wyche | director | 72500 2.1071% | $134,850.00 | 1 | 0 | +0.2% |
| Vieser Jaime | director | 25894 0.7526% | $48,162.84 | 2 | 1 | <0.0001% |
$6,974,678 | 45 | -14.98% | $4.63M | |
$13,664,154 | 40 | -70.35% | $7.05M | |
$29,645,465 | 28 | 8.09% | $6.48M | |
Alaunos Therapeutics, Inc. (TCRT) | $63,749,694 | 24 | -12.24% | $6.4M |
$287,718 | 15 | -41.45% | $5.68M |
| Increased Positions | 8 | +22.86% | 44,326 | +67.75% |
| Decreased Positions | 11 | -31.43% | 1,206 | -1.84% |
| New Positions | 6 | New | 31,292 | New |
| Sold Out Positions | 5 | Sold Out | 296 | Sold Out |
| Total Postitions | 32 | -8.57% | 108,550 | +65.9% |
| Blackrock, Inc. | $70.00 | 1.07% | 21,353 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $69.00 | 1.05% | 20,972 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $52.00 | 0.79% | 15,791 | -155 | -0.97% | 2025-09-30 |
| Morgan Stanley | $6.00 | 0.08% | 1,684 | -114 | -6.34% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $5.00 | 0.08% | 1,633 | +660 | +67.83% | 2025-09-30 |
| Ubs Group Ag | $5.00 | 0.08% | 1,533 | -5,282 | -77.51% | 2025-09-30 |
| Osaic Holdings, Inc. | $4.00 | 0.06% | 1,165 | +470 | +67.63% | 2025-09-30 |
| Cibc Private Wealth Group Llc | $1.00 | 0.02% | 300 | 0 | 0% | 2025-09-30 |
| Royal Bank Of Canada | $1.00 | 0.01% | 198 | +198 | New | 2025-09-30 |
| Wells Fargo & Company/Mn | $1.00 | 0.01% | 183 | 0 | 0% | 2025-09-30 |